DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae CURRICULUM VITAE Mustafa F. Lokhandwala, Ph.D. EDUCATION Degree Year Institution Field B.Pharm 1966 L.M.College of Pharmacy Pharmacy Ahmedabad, India M.S. l968 Columbia University Pharmacology New York, New York Ph.D. 1975 University of Houston Pharmacology Houston, Texas PROFESSIONAL APPOINTMENTS Title Institution Dates Dean College of Pharmacy 2008-2009 University of Houston Director Heart and Kidney Institute 2006-present University of Houston Executive Vice Dean College of Pharmacy 2003-present For Research University of Houston Dean College of Pharmacy 1991-2002 University of Houston Professor Department of Pharmacology 1989-present University of Houston Chairman Department of Pharmacology 1980-1991 University of Houston Associate Professor Department of Pharmacology 1981-1989 University of Houston Assistant Professor Department of Pharmacology 1975-1981 University of Houston Research Assistant Department of Pharmacology 1970-1971 Columbia University/Ciba-Geigy New York and Tuckhoe, N.Y. OTHER APPOINTMENTS Adjunct Professor Hypertension & Clinical Pharmacology 1989-present Baylor College of Medicine Houston, Texas Adjunct Associate Hypertension & Clinical Pharmacology 1986-1989 Professor Baylor College of Medicine Houston, Texas Visiting Professor University of Rome September, 1989 Rome, Italy Visiting Professor The Third Military Medical University March, 2007 Chongqing, P.R.China RESEARCH INTERESTS, TRAINING AND TECHNIQUES Cardiovascular and Renal Pharmacology Hypertension and Antihypertensive Drug Mechanisms Central and peripheral control of the cardiovascular and renal function Role of oxidative stress in hypertension, diabetes and aging - receptor-G protein coupling - drug responsiveness - antioxidant supplementation - redox imbalance and role of transcription factors - activators of antioxidant responsive elements Dopamine, Dopamine Receptor Agonists and Cardiovascular Function Dopamine receptor function in obesity, diabetes, hypertension and aging Dopamine receptor mediated cellular signalling mechanisms in the proximal tubule Role of kidney dopamine in sodium balance and control of blood pressure Oxidative stress and D1 receptor signal transduction in the kidney Research Techniques Measurements of inflammatory, reactive oxygen species and several biomarkers in hypertension, aging and diabetes In vivo measurements of cardiac function including output, contractility Measurements of venous return and vascylar rsistance in various beds Sympathetic nerve stimulation induced changes in cardiac and renal function Measurements of renal function including renal plasma flow, glomerular filtration rate, sodium excretion, pressure natriuresis relationships 2 Cardiovascular and renal responses to drugs and other maneuvers in models of diabetes, hypertension and aging. Research Accomplishments Identification of presynaptic dopamine receptors on sympathetic nerve terminals under in vivo conditions and the demonstration that activation of these receptors was responsible, at least in part for the vasodilator action of dopamine. Demonstration of the uncoupling of D1 receptor in proximal tubule from the G-protein in hypertension and in aging Hyperglycemia and hyperinsulinemia contribute to receptor-G protein uncoupling in type I and type II diabetes, respectively. Improvement of insulin sensitivity in diabetic rats with drug therapy restores D1 receptor-G protein coupling and renal responsiveness to dopamine. The mechanism by which oxidative stress and inflammation contribute to various diseases: Studies on the role of NFkB, Nrf2 and Phase II antioxidant enzymes. AWARDS & HONORS University of Houston chapter of Sigma Xi, The Scientific Research Society’s Research Excellence Award for 1993. Individual Educational Excellence Award, Texas Pharmacy Foundation, 2000 Robert A. Boblitt Rho Chi Lectutre, 2004 TEACHING EXPERIENCE Pharmacology Principles of Drug Action Hypertension/Antihypertensive Agents Angina/Antianginal Agents Graduate Courses Adrenergic/Cholinergic Pharmacology Cardiovascular pharmacology Cardiovascular research techniques Advances in renal pharmacology GRADUATE STUDENTS 3 A. A. Martinez, Ph.D. (l980) Dissertation title: Involvement of sympathetic nervous system in the cardiovascular actions of 5-hydroxytryptamine G. J. Hom, M.S. (l980) Thesis title: Presynaptic inhibition of sympathetic nervous system by adenosine: physiological & pharmacological implications S. J. Augustine, M.S. (l98l) Thesis title Characteristics and mechanisms of clonidine withdrawal in normotensive and hypertensive rats A.T. Hamed, Ph.D. (l98l) Dissertation title: Pharmacological significance of cardiovascular dopamine receptors R. J. Barrett, Ph.D. (l982) Dissertation title: Role of sympathetic nervous system dopamine receptors in the cardiovascular actions of lergotrile and pergolide E. J. Peter, M.S. (l984) Thesis title: Pharmacological analysis of the actions of calcium entry blockers felodipine, nifedipine and verapamil: Interactions with pre and postsynaptic alpha adrenoceptors. S. Sengupta, M.S. (1985) Thesis title: Pharmacological characterization of the cardiovascular actions of dopamine receptor agonists, fenoldopam and quinpirole in rats. M. H. Sabouni, Ph.D. (1986) Dissertation title: Pharmacological characterization of dopamine receptors in the sympathetic ganglia G. Kavukondala, M.S. (1986) Thesis title: The role of Na+-K+-ATPase in the regulation of sympathetic neuro- effector function in the isolated perfused rat kidney S. S. Hegde, Ph.D. (1990) Dissertation title: Renal dopamine in the regulation of sodium and water excretion during acute volume expansion S. J. Vyas, Ph.D. (1992) Dissertation title: Involvement of tubular DA-1 receptors in the natriuretic and diuretic responses to dopamine and dopexamine: Role of Phospholipase-C in cellular signaling events C. J. Chen, M.D. Ph.D. (1992) Dissertation title: Dopamine receptor- coupled cellular signaling mechanisms in renal proximal tubules of spontaneously hypertensive rats S. Gopalakrishnan, M.S. (1994) Thesis title: Alpha-1 adrenoceptors in the renal proximal tubules: Characterization and cellular signaling mechnisms 4 U. Venkatakrishnan, M.S. (1994) Thesis title: The role of nitric oxide in the diuretic and natriuretic responses to dopamine-1 receptor activation V. Kansra, M.S. (1995) Thesis title: Dopamine stimulates protein kinase C activity in normotensive but not in hypertensive rats M. Bharatula, M.S. (1996) Thesis title: Characterization of Angiotensin Type I (AT1) Receptor Subtypes in the Biphasic Effect of Angiotensin II on Renal Proximal Tubular Sodium Potassium ATPase V. Kansra, Ph.D. (1997) Dissertation title: Renal dopamine receptor signaling mechanisms in Fisher 344 old rats S. Beheray, Ph.D. (1999) Dissertation title: Age related alterations in dopamine receptor-mediated signaling pathways in renal proximal tubules M. Becker M.S. (1999) Alterations in angiotensin II receptor mediated signaling pathways in the renal proximal tubules of obese Zucker hypertensive rats V. Narkar Ph.D. (2002) Dissertation title: Dopamine D2 receptor signaling and function in renal proximal tubules M. Menezes M.S. (2002) Thesis title: Alterations in dopamine D2-like receptor signaling mechanisms in renal proximal tubules of Fischer 344 rats. M. Trivedi Pharm.D. / Ph.D. (2004) Renal dopamine receptor dysfunction in obese Zucker rats. A. Marwaha Ph.D. (2005) Renal dopamine D1 receptor function in hyperglycemia associated oxidative stress R. Fardoun Pharm.D. / Ph.D. (2006) Cellular mechanisms of oxidative stress-induced defective renal dopamine D1 receptor function A. B. Muhammad Ph.D. (2010) Effect of exercise and caloric restriction on renal dopamine D1 receptor function in obese Zucker rats. L. George Pharm.D. / Ph.D. (2010) Mechanism of exercize-mediated restoration of renal dopamine D1 receptor function in aging. 5 S. Bhatt Ph.D. (2011) Vascular oxidative stress in hyoertension G. Chough Ph.D. (2011) Role of age-associated oxidative stress in altered renal D1 and AT1 receptor fuhctions and hypertension. A. Javedhkar Ph.D. (2011) Oxidative stress and renal AT1 receptor function during hypertension. POSTDOCTORAL FELLOWS AND RESEARCH FACULTY Dr. R. D. Ekas 1978-1982 Dr. D. C. Eikenburg 1979-1981 Dr. A. L. Jadhav 1981-1988 Dr. S. Tachikawa 1981-1982 Dr. J. L. Montastruc 1982 Dr. H. O. Watkins 1982-1990 Dr. A. F. Ansari 1984-1985 Dr. G. D. Adjei 1984 Dr. A. T. Hamed 1985 Dr. M. L. DeFeo 1986-1987 Dr. T. Sakamoto 1991-1992 Dr. A. T. Hamed 1992-1993 Dr. C. J. Chen 1992-1994 Dr. T. Hussain 1995-2001 Dr. M. Asghar 1999-present Dr. L. Zhang 2001-2002 Dr. A. Banday 2001-present Dr. A Marwaha 2005-2006 6 GRANT & CONTRACTS Studies on the mechanisms of antihypertensive action of various beta adrenergic blocking agents From: New Research Opportunities Program University of Houston $4,518; 1/1/76 to l2/31/76 Studies on the functional role of presynaptic beta adrenergic receptor mechanism in sympathetic neurtoransmission From: Pharmaceutical Manufacturers Association Foundation Washington, DC $10,000; 1/1/77 to 12/31/78 Vascular reactivity in experimental hypertension From: American Heart Association; Texas Affiliate, Inc. Austin, Texas $12,685; 7/l/78 to 6/30/79 Presynaptic regulatory mechanisms in hypertension From: National Heart, Lung and Blood Institute; National Institutes of Health Bethesda, MD $194,242; 7/l/78 to l2/31/82 The role of sympathetic nervous system in the cardiovascular actions of dopaminergic agents From: Eli Lilly & Co. Indianapolis, Indiana $7,l75; 7/1/81 to 6/30/84 Studies
Load more

Recommended publications
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,723,065 B2 Trewhella Et A]
    US007723065B2 (12) United States Patent (10) Patent N0.: US 7,723,065 B2 Trewhella et a]. (45) Date of Patent: May 25, 2010 (54) CONDITIONS FOR REACTIONS MEDIATED Kumar A, Ner DH, Dike SY, A New Chemoenzymatic Enantioselec BY YEAST tive Synthesis of R-(—)-Tomoxetine, R- and S-Fluoxetine, Tetrahe dron Letters, 1991, 32(16): 1901-1904.* (75) Inventors: Maurice Arthur TreWhella, Hoppers Liu X, Zhu T-S, Sun P-D, Xu J-H, Asymmetric Reduction of Aro Crossing (AU); Nick Athanasiou, matic Ketones by the Baker’s Yeast in Organic Solvent Systems, Yarraville (AU); Andrew John Synthetic Communications, 2001, 31(10): 1521-1526.* Smallridge, Hampton East (AU) Chem 231 Lecture No. 10 Sp 1999* Ohta et al. “Asymmeteric Reduction of Nitro Ole?ns by Fermment (73) Assignee: Victoria University, Victoria (AU) ing Baker’sYeast.” J. Org. Chem. vol. 54, pp. 1802-1804. 1989* ( * ) Notice: Subject to any disclaimer, the term of this KaWai et al. “Asymmeteric Reduction of nitroalkenes With baker’s patent is extended or adjusted under 35 yeast.” Tetrahedron: Asymmetry. vol. 12, pp. 309-318. 2001.* U.S.C. 154(b) by 933 days. Y. Gao and K. B. Sharpless-“Asymmetric Synthesis of Both Enantionmers of Tomoxentine and Fluoxentine. Selective Reduction of 2, 3-Epoxycinnamyl Alcohol With Red-A1”, J. Org. Chem. 1988, (21) Appl.No.: 10/814,891 53, 4081-4084. © 1988 American Chemical Society. (22) Filed: Mar. 31, 2004 Badan S. Deol et al., Asymmetric Reduction of Carbonyl Compounds byYeast. II; Aust. J. Chem., 1976, 29, 2459-67, 9 pages. (65) Prior Publication Data * cited by examiner US 2005/0084943 A1 Apr.
    [Show full text]
  • Treatment for Calcium Channel Blocker Poisoning: a Systematic Review
    Clinical Toxicology (2014), 52, 926–944 Copyright © 2014 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2014.965827 REVIEW ARTICLE Treatment for calcium channel blocker poisoning: A systematic review M. ST-ONGE , 1,2,3 P.-A. DUB É , 4,5,6 S. GOSSELIN ,7,8,9 C. GUIMONT , 10 J. GODWIN , 1,3 P. M. ARCHAMBAULT , 11,12,13,14 J.-M. CHAUNY , 15,16 A. J. FRENETTE , 15,17 M. DARVEAU , 18 N. LE SAGE , 10,14 J. POITRAS , 11,12 J. PROVENCHER , 19 D. N. JUURLINK , 1,20,21 and R. BLAIS 7 1 Ontario and Manitoba Poison Centre, Toronto, ON, Canada 2 Institute of Medical Science, University of Toronto, Toronto, ON, Canada 3 Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada 4 Direction of Environmental Health and Toxicology, Institut national de sant é publique du Qu é bec, Qu é bec, QC, Canada 5 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 6 Faculty of Pharmacy, Université Laval, Qu é bec, QC, Canada 7 Centre antipoison du Qu é bec, Qu é bec, QC, Canada 8 Department of Medicine, McGill University, Montr é al, QC, Canada 9 Toxicology Consulting Service, McGill University Health Centre, Montr é al, QC, Canada 10 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 11 Centre de sant é et services sociaux Alphonse-Desjardins (CHAU de Lévis), L é vis, QC, Canada 12 Department of Family Medicine and Emergency Medicine, Universit é Laval, Québec, QC, Canada 13 Division de soins intensifs, Universit é Laval, Qu é bec, QC, Canada 14 Populations
    [Show full text]
  • Role of Selective Α and Β Adrenergic Receptor Mechanisms in Rat Jejunal Longitudinal Muscle Contractility
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library J Gastrointest Surg (2008) 12:1087–1093 DOI 10.1007/s11605-007-0327-4 Role of Selective α and β Adrenergic Receptor Mechanisms in Rat Jejunal Longitudinal Muscle Contractility Roland Seiler & Andreas Rickenbacher & Sidney Shaw & Simon Haefliger & Bruno M. Balsiger Received: 29 August 2007 /Accepted: 5 September 2007 /Published online: 19 September 2007 # 2007 The Society for Surgery of the Alimentary Tract Abstract Gut motility is modulated by adrenergic mechanisms. The aim of our study was to examine mechanisms of selective adrenergic receptors in rat jejunum. Spontaneous contractile activity of longitudinal muscle strips from rat jejunum was measured in 5-ml tissue chambers. Dose–responses (six doses, 10−7–3×10−5M) to norepinephrine (NE, nonspecific), phenylephrine (PH, α1), clonidine (C, α2), prenalterol (PR, β1), ritodrine (RI, β2), and ZD7714 (ZD, β3) were evaluated with and without tetrodotoxin (TTX, nerve blocker). NE(3 × 10−5M) inhibited 74 ± 5% (mean ± SEM) of spontaneous activity. This was the maximum effect. The same dose of RI(β2), PH(α1), or ZD(β3) resulted in an inhibition of only 56 ± 5, 43 ± 4, 33 ± 6, respectively. The calculated concentration to induce 50% inhibition (EC50) of ZD(β3) was similar to NE, whereas higher concentrations of PH(α1) or RI(β2) were required. C(α2) and PR(β1) had no effect. TTX changed exclusively the EC50 of RI from 4.4 ± 0.2 to 2.7 ± 0.8% (p < 0.04). Contractility was inhibited by NE (nonspecific).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Beta-2 Adrenergic Effects on the Sympathetic Nervous System
    BETA-2 ADRENERGIC EFFECTS ON THE SYMPATHETIC NERVOUS SYSTEM. Beta-2 Adrenerge Effecten op het Sympathische Zenuwstelsel PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. Dr. A.H.G. Rinnooy Kan en volgens besluit van het college van dekanen. De openbare verdediging zal plaatsvinden op woensdag 3 mei 1989 om 13.45 uur door Hieronymus Henricus Vincent geboren te Schiedam. 1 PROMOTIE-COMMISSIE Promotor: Prof. Dr. M. A.. D. H. Schalekamp Overige leden: Prof. Dr. W.H. Birkenhäger Prof. Dr. P.R. Saxena Dr. Th.A. Thien 2 CONTENTS Chapter 1: Introduetion .••.•...••...•.....•...•......• 5 Chapter 2: Elevated plasma noradrenaline in response to beta adrenoceptor stimulation in man ....•...•........ l3 Chapter 3: Effects of selective and non-selective beta agonists on plasma potassium and norepinephrine ...... l8 Chapter 4: Stress levels of adrenaline amplify the blood pressure response to sympathetic stimulation ... 26 Chapter 5: Is beta-l antagonism essential to the antihypertensive action of betablockers? ........... 32 Chapter 6: Beta-2 agonists increase plasma renin through beta-l adrenoceptor activatien by transmitter noradrenaline. Evidence for functional presynaptic beta recepters in the kidney ..•.••....•...••....• , ........ 3 8 Chapter 7: General discussion ........................ 52 Chapter 8: Samenvatting ..•.......•........••......... 60 Curriculum vitae .••.•.•....•..•.•.•.•..•........•...• 68 Dankwoord .......•..•....•..•....•...•................ 6 9 3 4 Chapter 1 INTRODUeTION The origin of the studies, described in this thesis, dates back to 1979. In that year my colleague, R.P. Verhoeven, studied the responsiveness of hyperthyroid patients to beta adrenoceptor activation [1]. In his experiments he made the serendipitous observation that the plasma levels of the sympathetic transmitter, noradrenaline, increased during infusion of the beta adrenoceptor agonist isoprenaline.
    [Show full text]
  • II the Thermodynamics of Efficacy and Ligand Proton Transfer
    Towards a Thermodynamic Definition of Efficacy in Partial Agonism: II The Thermodynamics of Efficacy and Ligand Proton Transfer in a G Protein-coupled Receptor of the Rhodopsin Class Kenneth J. Broadley, Shane C. Sykes, Robin H. Davies To cite this version: Kenneth J. Broadley, Shane C. Sykes, Robin H. Davies. Towards a Thermodynamic Definition of Efficacy in Partial Agonism: II The Thermodynamics of Efficacy and Ligand Proton Transferina G Protein-coupled Receptor of the Rhodopsin Class. Biochemical Pharmacology, Elsevier, 2010, 80 (10), pp.1537. 10.1016/j.bcp.2010.07.044. hal-00626230 HAL Id: hal-00626230 https://hal.archives-ouvertes.fr/hal-00626230 Submitted on 24 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: Towards a Thermodynamic Definition of Efficacy in Partial Agonism: II The Thermodynamics of Efficacy and Ligand Proton Transfer in a G Protein-coupled Receptor of the Rhodopsin Class Authors: Kenneth J. Broadley, Shane C. Sykes, Robin H. Davies PII: S0006-2952(10)00583-6 DOI: doi:10.1016/j.bcp.2010.07.044 Reference: BCP 10678 To appear in: BCP Received date: 28-6-2010 Accepted date: 21-7-2010 Please cite this article as: Broadley KJ, Sykes SC, Davies RH, Towards a Thermodynamic Definition of Efficacy in Partial Agonism: II The Thermodynamics of Efficacy and Ligand Proton Transfer in a G Protein-coupled Receptor of the Rhodopsin Class, Biochemical Pharmacology (2010), doi:10.1016/j.bcp.2010.07.044 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Sympathetic NS
    Pharmacology of the Autonomic Nervous System Indented = similar action to parent compound italic = less important agent [ ] = questionable therapeutic value I =drug interactions S = side effects T = toxicity CV = cardiovascular system CNS = central nervous system Agent (trade name®) Therapeutic Use Notes E. Ishac Adrenoceptor Agonists MAOI = Monoamine oxidase inhibitors TCA = Tricyclic antidepressants Norepinephrine (Levarterenol) Hypotension, pressor agent α / β1 β3 (β2) neuronal, non-circulating, I: MAOI, TCA Epinephrine (generic) Allergic reactions, shock, CPR α / β1 β2 (β3) adrenal medulla, circulating; I: MAOI, TCA Dopamine (Intropin) Renal vasodilatation during shock α1 / β1 / D, precursor to NE, I: MAOI Isoproterenol (Isuprel) Asthma, cardiac stimulant β, synthetic, not endogenous; (↓, --) BP HR Phenylephrine (Neosynephrine) Nasal decongestant, hypotension not commonly used for hypotension; S: CV, reflex Methoxamine (Vasoxyl) Hypotension, pressor agent bradycardia Metaraminol (Aramine) Hypotension, pressor agent α, orally active; NE or DA better choice Clonidine (Catapres) Hypertension α2, ↓ cns sympathetic outflow, inhibit NE release, Guanfacine (Tenex) rebound HT; S: dry mouth, sedation, impotence. α-methyl-dopa is metabolized to α-methyl-NE (α - α 2 -methyl-dopa (Aldomet) agonist) Dobutamine (Dobutrex) CHF, cardiac stimulant β1, iv infusion, tolerance, desensitization Prenalterol Terbutaline (Brethaire) Asthma, premature labor β2-selective, Oral 1-2 hrs onset ! 4-6 hrs duration, Ritodrine (Yutopar) Premature labor Inhalation
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • The Classification of Drugs and Drug Receptors in Isolated Tissues
    0031-6997/84/3603-0165$02.00/0 PHARMACOLOGICAL REVIEWS Vol. 36, No.3 Copyright © 1984 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. The Classification of Drugs and Drug Receptors in Isolated Tissues TERRY P. KENAKIN Department of Pharmacology, The Welkome Research Laboratories, Burroughs Welkome Co., Research Triangle Park, North Carolina I. Introduction 165 A. Isolated tissue and binding studies 166 II. Factors in the choice of isolated tissues 167 A. Animals 167 B. Preservation of tissue viability 167 C. Some isolated tissues from animals and man 168 D. Methods of tissue preparation 168 E. Measurement of tissue responses 172 F. Sources of variation in tissues 172 1. Heterogeneous receptor distribution 172 2. Animal maturity 173 G. Comparisons between isolated tissues 173 Downloaded from III. Equilibrium conditions in isolated tissues 173 A. Chemical degradation of drugs 174 B. Release of endogenous substances 174 C. Removal of drugs by tissues 176 1. Diffusion into isolated tissues 176 2. Drug removal processes in isolated tissues 177 by guest on June 7, 2018 3. Consequences of uptake inhibition in isolated tissues 179 IV. Quantification of responses of agonists 183 A. Dose-response curves 183 B. Drug receptor theory 184 C. The relationship between stimulus and response 185 1. Tissue response as a function of stimulus 185 2. Receptor density 188 V. Methods of drug receptor classification 188 A. Agonist potency ratios 188 B. Selective agonism 189 C. Measurement of agonist affinity and relative efficacy 192 1. Agonist affinity 192 2. Agonist efficacy 195 3. Experimental manipulation of receptor number and efficiency of stimulus response coupling 196 D.
    [Show full text]